GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Connect Biopharma Holdings Ltd (NAS:CNTB) » Definitions » DeferredTaxAndRevenue

Connect Biopharma Holdings (Connect Biopharma Holdings) DeferredTaxAndRevenue : $13.32 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Connect Biopharma Holdings DeferredTaxAndRevenue?

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Connect Biopharma Holdings's current deferred tax and revenue for the quarter that ended in Dec. 2023 was $13.32 Mil.

Connect Biopharma Holdings DeferredTaxAndRevenue Historical Data

The historical data trend for Connect Biopharma Holdings's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Connect Biopharma Holdings DeferredTaxAndRevenue Chart

Connect Biopharma Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
DeferredTaxAndRevenue
- - - - 13.32

Connect Biopharma Holdings Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
DeferredTaxAndRevenue Get a 7-Day Free Trial Premium Member Only - - - - 13.32

Connect Biopharma Holdings DeferredTaxAndRevenue Related Terms

Thank you for viewing the detailed overview of Connect Biopharma Holdings's DeferredTaxAndRevenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Connect Biopharma Holdings (Connect Biopharma Holdings) Business Description

Traded in Other Exchanges
N/A
Address
12265 El Camino Real, Suite 350, San Diego, CA, USA, 92130
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.

Connect Biopharma Holdings (Connect Biopharma Holdings) Headlines